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Abstract
Bloating is one of the most common and bothersome 
symptoms complained by a large proportion of pa-
tients. This symptom has been described with various 
definitions, such as sensation of a distended abdo-
men or an abdominal tension or even excessive gas in 
the abdomen, although bloating should probably be 
defined as the feeling (e.g.  a subjective sensation) of 
increased pressure within the abdomen. It is usually 
associated with functional gastrointestinal disorders, 
like irritable bowel syndrome, but when bloating is not 
part of another functional bowel or gastrointestinal dis-
order it is included as an independent entity in Rome 
Ⅲ criteria named functional bloating. In terms of diag-
nosis, major difficulties are due to the lack of measur-
able parameters to assess and grade this symptom. In 
addition, it is still unclear to what extent the individual 
patient complaint of subjective bloating correlates with 
the objective evidence of abdominal distension. In 
fact, despite its clinical, social and economic relevance, 
bloating lacks a clear pathophysiology explanation, 
and an effective management endorsement, turning 
this common symptom into a true challenge for both 
patients and clinicians. Different theories on bloat-
ing etiology call into questions an increased luminal 
contents (gas, stools, liquid or fat) and/or an impaired 
abdominal empting and/or an altered intra-abdominal 
volume displacement (abdomino-phrenic theory) and/
or an increased perception of intestinal stimuli with a 
subsequent use of empirical treatments (diet modifica-
tions, antibiotics and/or probiotics, prokinetic drugs, 
antispasmodics, gas reducing agents and tricyclic an-
tidepressants). In this review, our aim was to review 
the latest knowledge on bloating physiopathology and 
therapeutic options trying to shed lights on those pro-
cesses where a clinician could intervene to modify dis-
ease course.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: Bloating is one of the most common and both-
ersome symptoms complained by a large proportion of 
patients, mostly with functional gastrointestinal disor-
ders, but when bloating is not part of another function-
al bowel or gastrointestinal disorder it is included as 
an independent entity in Rome Ⅲ criteria named func-
tional bloating. Despite its clinical, social and economic 
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relevance, bloating lacks a clear pathophysiology ex-
planation and an effective management endorsement. 
Moreover, it is unclear to what extent subjective com-
plaint of bloating correlates with the objective evidence 
of abdominal distension. The aim of this paper is to 
review the latest knowledge on bloating and to explore 
future research directions to improve its management.
Iovino P, Bucci C, Tremolaterra F, Santonicola A, Chiarioni 
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are we and where are we going? World J Gastroenterol 2014; 
20(39): 14407-14419  Available from: URL: http://www.wjgnet.
com/1007-9327/full/v20/i39/14407.htm  DOI: http://dx.doi.
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Background
There is no consensus concerning the definition of  bloat-
ing which is a term very ambiguous both in English and 
in other languages. Patients refer bloating when they feel 
a full and tight abdomen, or a sensation of  a swollen/
distended abdomen, or an abdominal pressure or wall 
tension, or even the sensation of  excessive gas in the ab-
domen. Furthermore, other complains such as burping 
and belching which reflect the expulsion of  excess gas 
from the stomach, nausea, crampy, gurgling, or rumbling 
stomach; or needing to go to the bathroom are mislead-
ing with bloating from patient’s perspective. The defini-
tion of  bloating should probably be regarded as meaning 
that there is a feeling (subjective sensation) of  increased 
pressure within the abdomen, whereas abdominal disten-
sion should be reserved to an actual (objective) increase 
in diameter of  the abdominal area. While often consid-
ered closely related, bloating is not always accompanied 
by visible distention[1,2]. However, irrespective of  whether 
bloating is or is not accompanied by distension, patients 
usually refer to it as bloating and currently even clinicians 
tend to use the term bloating to cover both features.
Bloating is also reported in organic diseases such as 
enteropathogenic infections, malabsorptive conditions, 
acute or subacute bowel ischemia, and even neoplastic dis-
eases. Bloating has been shown to be even useful for the 
early diagnosis of  ovarian cancer and falls into a specific 
ovarian cancer symptoms index to its earlier detection, 
while it remains an unspecific signal for gastro-intestinal 
tumors[1-4].
Bloating is one of  the most common and bothersome 
complaints in a large proportion of  patients with various 
functional gastro-intestinal disorders (FGIDs), namely: 
functional dyspepsia (FD)[5,6], irritable bowel syndrome 
(IBS)[5-7], and functional constipation[5,6,8]. Up to 80% of  
patients with constipation complain of  bloating and ab-
dominal distension[9,10]. However, bloating in the absence 
of  visible distension is frequently reported by patients 
with diarrhea[11]. Bloating is one of  the principal symp-
toms of  postprandial distress syndrome, one of  the two 
subgroups of  FD, where it is often located in the upper 
abdomen and precipitated by meals[6,12].
When bloating is not part of  another functional bow-
el or gastroduodenal disorder, functional bloating is also 
included as an independent entity in Rome Ⅲ criteria[13]. 
In details, its diagnostic criteria include recurrent feeling 
of  bloating or visible distension at least 3 d a month in 
the last 3 mo with symptom onset at least 6 mo prior to 
diagnosis[13]. The name has been changed from functional 
abdominal bloating in Rome Ⅰ and Ⅱ criteria to func-
tional bloating in Rome Ⅲ criteria[13].
Epidemiologically, one in six to one in five healthy 
individual reported bloating in population based studies 
both in western[14,15] and east countries[16]. This prevalence 
dramatically increases, being reported by up to 96% in 
IBS patients[7]. Also, the majority of  those patients (60%) 
rate bloating as their most bothersome symptom, scoring 
worse than abdominal pain[17].
Finally, there is some evidence documenting the asso-
ciation between bloating and quality of  life[18]. However, 
only abdominal pain and diarrhea, but not bloating and 
other IBS related symptoms, were independently associ-
ated with reduced quality of  life[19,20].
Typically, the symptom is variably reported over the 
months and fluctuates in intensity over daytime, particu-
larly in the postprandial period, being worse at the end 
of  the day and improving at night-time[11,21]. Changes in 
abdominal girth are greater in patients with IBS, and these 
patients are more likely to be symptomatic[22]. The severity 
of  bloating may, therefore, vary from very mild to severe 
and uncomfortable[15]. In addition, most of  the patients 
report typical symptom exacerbation after eating, no mat-
ter the size of  the meal assumed[22,23]. High-fiber food 
and supplements, fatty meals and dairy products are fre-
quently reported as offending[24,25]. Bloating symptoms are 
described more frequently by women[11,26,27] with a female 
to male ratio of  2:1[26,27], but this may be due to divergent 
health-seeking behaviors[28].
Despite its clinical, social and economic relevance[29], 
the pathophysiology of  bloating and abdominal disten-
sion is complicated and incompletely understood, and no 
treatment is reported as universally effective. However, 
with the increasing knowledge of  these disorders due to 
more objective ways of  assessing it in combination with 
the availability of  several new therapies over the past 
decade[30], we aim to review the latest knowledge on pa-
tophysiological mechanisms of  bloating, and to explore 
present and future research directions aimed on improv-
ing its management.
We reviewed the literature of  mechanisms and treat-
ment interventions for abdominal bloating based on 
a PubMed search on the following terms; “abdominal 
bloating,” “intestinal gas and IBS,” “distension and IBS” 
and “FGID.”
PathoPhysiology
Bloating, like many other abdominal symptoms, is prob-
ably a heterogeneous condition produced by a combi-
nation of  pathophysiological mechanisms that differ 
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among individuals.
Different theories on bloating/abdominal distension 
etiology have been postulated (Figure 1), incriminating 
time after time as (1) increased luminal contents (gas, 
stools, liquid or fat); (2) impaired abdominal empting (e.g., 
defective propulsion, obstructed evacuation); (3) altered 
intra-abdominal volume displacement (abdomino-phren-
ic theory); and/or (4) increased perception of  intestinal 
stimuli (sensory dysfunction or psychological factors).
Increased luminal contents
Gas: It can be speculated that bloating and, even more, 
abdominal distension depend on an increase in intra-
abdominal contents. Since years considering the rapidly 
changing and fluctuating trend of  such symptoms, gas 
has been always considered the element most heavily im-
plicated in explaining them.
The homeostasis of  intestinal gas depends on the bal-
ance between its formation and elimination. Briefly, gas 
input results at different level in the human being. For 
example, it results from swallowed air, chemical reactions 
(specifically, neutralization of  acids and alkali in the up-
per gut), and diffusion from bloodstream. In the lower 
part of  the GI tract it occurs primarily due to bacterial 
fermentation. Gas output is achieved by belching, ab-
sorption into the blood, bacterial consumption, and anal 
evacuation  (Figure 2)[31].
An excessive introduction of  gas, for example, occurs 
in aerophagia, a functional disorder in which patients 
swallow air so frequently and in such large quantities to 
result in symptoms of  abdominal distention and bloat-
ing[32]. Increased air swallowing, however, is either not or 
rarely observed in IBS patients[33]. Although not covered 
in this review, eating disorders may also be associated 
with symptoms of  gas and bloating[34].
Moreover, it has been shown that some food compo-
nents in the normal diet, such as resistant starch, oligo-
saccharides and plant fibres, are incompletely absorbed 
in the small bowel and enter the colon[35] with subse-
quent fermentation, and secondary bacterial overgrowth 
with abnormal fermentation of  foodstuffs within the 
small bowel or hyperactive colonic microflora. Some 
studies suggest that the absorption capacity of  certain 
substrates (e.g., fructose) in the small bowel is reduced in 
IBS patients[35-37]. However, studies evaluating the benefit 
of  exclusion diets on bloating have given contradictory 
results[38,39].
A potential small bowel bacterial overgrowth etiology 
has been suggested by some studies reporting increased 
positivity of  the lactulose breath test in IBS[40]. However, 
the relevance of  these data has been questioned for both 
the low reliability of  the test, the weak clinical response 
to antibiotic therapy and the low placebo effect com-
pared to other IBS studies[41]. However, there is general 
agreement that at least in a proportion of  patients with 
IBS and bloating[42-44] an increased bacterial fermentation 
can contribute to the symptoms[45].
The net effect of  colonic microflora on gas metabo-
lism depends on the balance between gas-producing and 
gas-consuming microorganisms, which varies consider-
ably among individuals[46].
For the most part, the colon hosts bacteria that pro-
duce hydrogen and carbon dioxide mainly from the fer-
mentation of  carbohydrates[47,48]. There is then, other 
pools of  colonic microorganisms, for example sulfate-
reducing bacteria, that consume a large proportion of  
the gases produced by fermentation and, release small 
amounts of  odoriferous sulfur-containing gas. About 
30% of  the population is also home to methane-produc-
ing bacteria that consume large quantities of  hydrogen 
and release methane[48-52]. Relevant factors contributing 
to the intraluminal gas homeostasis are: (1) the consume 
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Figure 1  Possible underlining mechanism behind bloating.
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of  gases (in particular hydrogen) by the bacteria strains; 
(2) the diffusibility of  single gases (greater for oxygen 
and the carbon dioxide, medium for hydrogen, low for 
nitrogen); and (3) the gas partial pressure and the time 
of  exposure to the diffusion surface which is influenced 
by intestinal transit speed[53,54]. Everything accounts for 
the gaseous composition of  flatus and is the basis for 
the hydrogen and methane breath tests.
However, evaluation of  intestinal gas production by 
breath tests has yielded inconclusive results. In one study 
breath hydrogen concentration was found to be similar 
in both IBS patients and healthy controls[55]. In contrast, 
another study measuring total excretion (breath plus 
anal) by indirect calorimetry showed that IBS patients 
excreted more hydrogen than healthy subjects when on 
a standard diet, suggesting an hyperactive gas-producing 
colonic microflora as potential etiology[45].
However, the stated increase in the production of  
intestinal gas should lead to an increase in flatulence but 
not necessarily of  bloating, in fact several studies show 
that most of  the normal subjects are able to excrete large 
amounts of  gas without complain of  symptoms[24,56]. 
Therefore, additional etiology factors are to be speculated 
in the genesis of  bloating.
In their early studies with the washout technique 
Lasser et al[57] showed that the amount (and composition) 
of  intestinal gas in IBS patients, in fasting condition, was 
similar to that of  healthy subjects, about 100-300 ml. In 
these studies, gas was measured by infusing argon into 
the intestine at a relatively high flow rate (40 mL/min) 
and recovering rectal gas. The Barcelona group more 
than twenty years later, using a gas challenge test Figure 
3), came to the same conclusion[58]. In contrast studies 
conducted using plain abdominal radiographs concluded 
that intra-abdominal gas content was larger in IBS pa-
tients than in healthy subjects[59,60]. However, the differ-
ences in the amount of  gas between the two groups, 
reported by these studies, appears to be relatively low in 
absolute volume and in addition these increases did not 
correlate with the symptoms reported. In fact, a com-
puted tomography study of  intestinal gas could not de-
tect significant differences between controls and patients 
with significant daytime abdominal girth increments and 
bloating[21].
These data suggest that clinical bloating may not be 
simply the result of  too much intestinal gas, but abnor-
mal gas handling and distribution within the gut might 
play a relevant role as well.
Stools: Bloating is a frequent complains in constipated 
patients[22]. Retained feces in the rectum causes delayed 
small intestinal as well as colonic transit, probably explain-
ing the aggravated bloating in constipated patients[61]. It 
has been previously suggested that anorectal dysfunction 
underlying functional constipation may be an important 
contributory factor to the development of  bloating and 
abdominal distension[62].
We found that in healthy men who underwent ex-
perimentally-controlled 35-d of  bed rest, at the end of  
the study, 60% had new onset of  functional constipation 
fulfilling Rome Ⅲ criteria, moreover, there was a signifi-
cant increase in flatulence and a significant correlation 
between the change in flatulence and the change in num-
ber of  evacuations that significantly decreased[63]. It is 
possible that during bed rest due to an ineffective evacua-















Figure 2  Gas physiology in the gastrointestinal tract. Gas input is deter-
mined by swallowing, chemical reactions (bacterial fermentation, food digestion) 
and diffusion from blood stream. Output is achieved by belching, absorption into 





Figure 3  Gas challenge test. The method consists in the infusion of a mixture 
of gases in the jejunum while anal gas output is quantified. Adapted from[65].
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tion of  stools, a larger amount of  faeces were retained in 
the rectum, then causing rectal distension and explaining 
the decreased bowel frequency and the increase in desire 
of  defecate along the experimental period. It is common 
knowledge that also normal subjects when provided with 
a sensation of  stooling may show a dyssynergic pattern 
of  defecation, particularly when tested in left lateral posi-
tion[64]. Since in healthy subjects experimentally-induced 
rectal distension accelerates gas evacuation and prevents 
gas retention[65], we hypothesized this mechanism un-
derlying the demonstrated increase in flatulence. In fact, 
intestinal gas handling is a dynamic and efficient process 
that allows the normal gut to accommodate and evacuate 
large gas loads without inducing symptoms[65].
Although the relationship between bloating/abdomi-
nal distension and constipation can be intuitive, contrast-
ing data have been published showing that also IBS-D 
patients claim for bloating. In 2006, Houghton et al[22] 
showed that in IBS patients there is a real increase in ab-
dominal circumference (up to 12 cm in IBS) compared 
to healthy subjects. However, a direct correlation among 
bloating, abdominal distension and girth increase was ev-
ident in IBS-constipation patient only. In this study, the 
relationship of  distension to subjective bloating showed 
a good correlation in constipation-predominant patients 
but not in diarrhea-predominant IBS[66]. Conflicting 
results were evidenced by Chang et al[11] who correlated 
IBS patterns with bloating and objective abdominal dis-
tension showing that patients complaining bloating plus 
abdominal distension were more frequently constipated 
(IBS-C), while those complaining of  simple bloating 
were more frequently diarrhea-predominant (IBS-D). 
These data has been subsequently confirmed by Jiang 
et al[14] who reported that IBS-C patients, compared to 
controls, experienced more frequently abdominal disten-
sion (14-fold more likely) than IBS-D who report more 
frequently bloating alone. In the attempt to explain pos-
sible underlining mechanisms, Authors again implicate 
an impaired colonic transit with subsequent bacterial 
overgrowth, fermentation and increased abdominal girth 
distension, even if  definitive data are still lacking.
Liquids: Once eaten, food is diluted in a large amount 
of  gastric secretion in order to suspend and disperse solid 
parts and facilitate digestion and absorption mechanisms. 
Typically, bloating patients do not claim for symptoms 
when fasten, but shortly after a meal. Thus one can specu-
late that the liquid, proximal, small bowel stimulation can 
be responsible for symptoms in bloating patients. More-
over, it has been shown that in bloating patients a liquid 
infusion of  lipids is associated with slow gut propulsive 
motility significantly more than in healthy individuals[67]. 
This stimulus seems to begin in the proximal small bowel 
for an impaired motor jejunum response, while distal il-
eum and colon are not affected by any change in motor 
patters. Moreover jejunal gas infusion, but not distal infu-
sions, was able to induce abdominal symptoms[68].
Fat: An excessive weight is known to be correlated with 
some clinical manifestations of  functional GI disorders, 
such as dyspepsia, however, the relationship between 
bloating and BMI is contradictory. Two clinical stud-
ies demonstrated that a BMI ≥ 30 positively correlates 
with bloating symptoms[69,70], while a recent meta-analysis 
showed that there was no relationship between bloating 
and increasing BMI[71].
Two interesting studies showed the possible associa-
tion between weight gain and bloating. In 1994, Sullivan 
et al[72] indicated that about 40% of  bloating complainers 
gained weight concurrently to the onset of  symptoms 
and, in 2001, Chang et al[11] found that 24% of  patients 
believed that their bloating symptoms began when weight 
started to increase. In our experience massive obese pa-
tients on a waiting list prior to bariatric surgery do not 
have a significant increase in intensity-frequency scores 
of  bloating and flatulence compared to controls[34]. Thus 
one can speculate that the recent fat accumulation in the 
abdomen, not massive obesity as chronic condition may 
favor the development or awareness of  bloating as a 
symptom.
Impaired abdominal empting
Even if  intestinal motility since long is recognized as one 
of  the key features in functional bowel disorders patho-
physiology[73], its central role can be questioned when it 
comes to bloating generation using conventional tech-
niques[74]. A recent study has also suggested that altered 
colon transit correlates poorly or not at all with IBS symp-
toms such as bloating, flatulence or pain[75]. On the other 
hand the Barcelona group has undertaken a series of  el-
egant studies on intestinal gas transit and tolerance, which 
have helped our understanding of  how gas might cause 
symptoms in IBS.
They have suggested that while gas volumes may be 
normal in patients with bloating, they have an impaired 
intestinal handling of  gas loads[57,67,76,77]. This may be of  
particular relevance since a sensory-motor gut abnormality 
might represent the pathophysiological basis of  bloating.
Lasser et al[57] evidenced that in a number of  patients 
complaining of  bloating the gas infused into the small 
bowel provokes both the flow back into the stomach of  
the gas and symptoms such as excessive gas, abdominal 
pain, and bloating. Over twenty years later, it has been 
shown that patients with IBS and functional bloating had 
impaired transit and tolerance of  intestinal gas[67,76,77]. For 
example, they retained gas and complaining about their 
usual symptoms in response to infusion of  gas, which was 
well tolerated by the majority of  healthy subjects. Interest-
ingly abdominal distension correlated with the volume of  
gas retained in their gut.
In healthy volunteers two important mechanisms have 
been demonstrated to give a possible explanation of  the 
mechanisms of  gas retention increased resistance to gas 
flow and impaired intestinal propulsion[77]. In particular, 
subjective abdominal complaints were much higher when 
14411 October 21, 2014|Volume 20|Issue 39|WJG|www.wjgnet.com
Iovino P et al . Bloating and functional gastro-intestinal disorders
it were produced by increased resistance to flow than 
when gas retention was induced by inhibition of  propul-
sion produced by glucagon-induced motor inhibition. 
Therefore, if  abdominal distention depends largely on 
the volume of  gas retained independently of  the mecha-
nism (i.e., high-resistance barrier obstructing flow or an 
impaired propulsion), symptom perception depends on 
the mechanism of  retention: at the same volumes, flow 
obstruction produces more symptoms than impaired pro-
pulsion. Conceivably, small gas bubbles, pushed against 
high-resistance barriers (maybe simultaneously at differ-
ent points of  the intestine), may increase intestinal wall 
tension and produce symptoms also by means of  a spa-
tial summation phenomena[58]. Hence a disorder involv-
ing the pelvic floor (defecation disorder) or the voluntary 
inhibition of  anal flatus, might contribute to gas retention 
and symptoms.
The origin of  such bowel motor alterations would 
be an abnormal reflex control. The transit of  gas seems 
to happen secondary to tonic motor activity and unre-
lated to phasic activity[65,74,78], finely regulated by gastro-
intestinal and intestine-intestinal reflexes[65,67,78-81]. Gas 
transit seems also being influenced by posture and physi-
cal activity[82-85], suggesting possible somato-visceral re-
flexes[80,81,86].
In healthy subjects it was shown that jejunal gas in-
fusion produced, on similar gas volume retained and 
abdominal distension, more symptoms than rectal infu-
sion[87]. These results indicate that the symptoms are influ-
enced by the segment in which the gas is trapped.
Moreover, studies performed with a scintigraphic tech-
nique, using Xenon 133, have shown that in patients 
with bloating there is a impaired small-intestinal propul-
sion of  gases[88], (interestingly the proximal small bowel 
is the site where are normally produced large amounts 
of  carbon dioxide). More recently this alteration in gas 
handling was detected in the proximal colon[86,89] that 
is the first physiological site of  colonic gas production. 
While alterations of  the aforementioned intestine-intes-
tinal reflexes could explain the small intestinal impaired 
gas transit[68,88], the proximal colon gas retention could 
be due to a proximal-to-distal uncoupling: low colon 
proximal tone, increased resistance to flow through the 
distal colon or both[77]. However, the clinical correlation 
remains unclear.
Altered intra-abdominal volume displacement
abdomino-phrenic theory: One of  the hypotheses for 
abdominal distension is that if  the distension is not related 
to increased luminal contents, but to gas displacement. 
In other words, the overall volume is still the same, but is 
shifted from its original position.
The abdomen is limited by the vertebral column, which 
determines the configuration of  the posterior abdominal 
wall, the diaphragm, and the anterolateral muscles. Fur-
thermore, it is intuitive that abdominal wall mechanics and 
postural activity are different in supine position compared 
when the trunk is erect.
It has been showed firstly that in healthy individuals, 
the increase of  intra-abdominal volume, using colonic gas 
infusion, causes girth enlargement and activates muscular 
contractions of  the anterior abdominal wall and that the 
same phenomena is impaired in bloating patients that 
showed an altered pattern of  abdominal contractions and 
an exaggerate girth increase caused by abdominal-wall 
dystony[90].
Subsequently, the same group tested in a series of  
elegant electromyographic (EMG) studies, the hypoth-
esis of  an impaired abdomino-phrenic coordination or 
abdomino-phrenic dyssynergia.
Using colonic gas infusions and EMG of  the dia-
phragm and of  the anterior wall, they found that in 
healthy individuals, studied in the in upright position, gas 
infusion causes a contraction of  the muscles in the anteri-
or abdominal wall (all except the internal oblique muscles 
already contracted as it exerts anti-gravitational activity)[90] 
and an adaptative relaxation of  the diaphragm[91] leading 
to a volumetric increase of  the abdominal cavity by an 
upper expansion and redistribution of  intra-abdominal 
contents to accommodate the extra volume load prevent-
ing an exaggerated girth increments. These changes were 
observed also during more physiological conditions such 
as meal ingestion[92]. In supine position, these responses 
to volume load express a similar posture-dependent coor-
dination: the diaphragm in this case contracts to exert an-
ti-gravitational activity while the anterior abdominal wall 
remains inactive. Conversely, in functional patients, by 
the same experimental model, was shown a paradoxical 
relaxation of  the anterior wall (inhibition of  the internal 
oblique without a significant contraction of  the rest of  
the anterior wall muscles)[90]. Moreover, by using a simul-
taneous abdominal CT scans observations in supine posi-
tion, a marked and significant diaphragmatic drop was 
evidenced which correlated with the degree of  anterior 
wall distension[93]. In particular, functional patients exhibit 
a paradoxical contraction of  the diaphragm (change in 
EMG activity) that in combination with relaxation of  the 
anterior wall muscles determined an altered redistribution 
of  luminal content (Figure 4). It was further proven a 
contribution of  the thorax to abdominal accommodation 
during gas load with a simultaneous intercostals muscles 
contraction coordinated with diaphragmatic relaxation and 
cephalad displacement, to increase thoracic perimeter[94]. 
These abnormal responses to gas load in patients, may be 
triggered by uncomfortable abdominal sensation[95,96]. So, 
even modest gas retention, alone or in conjunction with 
other factors such as meals, stress, etc., may induce symp-
toms and visible abdominal distension[8].
Increased perception of intestinal stimuli
Sensory dysfunction: As previously reported, patients 
with dyspepsia perceived and tolerated smaller meal vol-
umes than healthy subjects[97,98]. Perception of  intragas-
tric content depends on stimulation of  tension receptors 
in the gastric wall[99].
The difference between patients and healthy subjects 
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is more pronounced in the postprandial period because 
the presence of  nutrients increases visceral sensitivity 
in healthy subjects[100], but this effect is exaggerated in 
patients with dyspepsia[101]. Although during rectal disten-
sion not all IBS patients show visceral hypersensitivity, the 
presence of  an altered visceral sensitivity is considered 
greatly important in the pathogenesis of  IBS[10]. The gas 
challenge test proved a role of  sensory disturbances in IBS 
patients, and recent clinical experiment has demonstrated 
that bloating without visible distension is associated with 
visceral hypersensitivity[8]. Moreover, IBS patients with 
bloating pay more attention to their abdominal symp-
toms, which is a kind of  hyper-vigilance[102]. Therefore, al-
tered sensory threshold combined with altered conscious 
perception may explain the mechanism of  bloating. 
Moreover, a role for hormones has been hypothesized 
based on female predominance in IBS. Although healthy 
women may report changes in bowel function at the time 
of  menstruation, this effect is far more pronounced in 
women with IBS with approximately 40%-75% claim-
ing that bowel habit and bloating are exacerbated peri-
menstrually[11,72,103]. This suggests that bloating may be 
strongly influenced by hormonal status to modify visceral 
sensitivity. However, whether estrogens have pronocicep-
tive or antinociceptive properties is still a controversial 
issue[104].
Psycological factors: The role of  psychological fac-
tors in the etiology induction pathogenesis of  bloating 
is still controversial. Some authors reported a strong link 
between symptoms of  mental stress such as depression, 
sleeping difficulties, problems of  coping and abdominal 
complaints, including bloating, in IBS patients[105], al-
though this association was not confirmed by others[106].
Neri et al[107] rated abdominal bloating as one of  the 
six useful symptoms on discriminating functional bowel 
disorders. More recently, Jiang et al[14] reported higher 
Somatic Symptom Checklist (a measure of  somatiza-
tion) scores in patients with bloating and distension, 
suggesting that the process of  somatization could play 
a role. Further studies applying standardized psychiatric 
questionnaires and the Diagnostic and Statistical Manual 
of  Mental Disorders criteria are needed to clarify the 
possible association between psychological factors and 
bloating.
treatment
As a consequence of  unclear pathophysiological mecha-
nisms underlining bloating, the management remains 
mostly empiric. Currently, the primary therapeutic aim 
is limited on reducing gas production or accelerating 
colonic transit, but there is a lack of  concrete scientific 
basis. Also, there are few trails assessing relief  of  bloat-
ing as primary end point, thus therapeutic options derive 
from data extrapolated from IBS studies with a conse-
quent limited reliability.
A change in diet habits is commonly considered as 
first line therapy. Most of  the primary care patients have 
already tested the efficacy of  different exclusion diet be-
fore consulting a gastroenterologist. Among exclusion di-
ets, recent evidences suggest a strong role of  FODMAPs 
(fermentable oligosaccharides, disaccharides, monosac-
charides, and polyols) in the genesis of  IBS symptoms. 
Halmos et al[108] tested the effects of  a low FODMAPs 
diet in a randomized, controlled, single-blind, cross-over 
trial of  patients with IBS showing a reduction of  overall 
IBS symptoms, including bloating, pain and passage of  
gas[39].
Evidences of  a role of  physical activity on bloating 
symptoms were studied by the Barcelona group. They 
showed that mild physical activity and upright position ac-
celerate gas transit and reduce bloating and abdominal 
distension[87]. Theoretically, a change in hydrostatic forces 
distribution and increased intra-abdominal pressure dur-
ing upright position or a propulsive gut motor response 
induced by exercise, promote gas transit. Non-pharma-
cological agents showed inconstant results. We speculated 
that mechanical compression of  the abdominal wall could 
exert a passive effect on gas displacement and stimulate 
a propulsive gut motor response, making the gas evacua-
tion easier and the symptoms to reduce. On the contrary, 
our data demonstrated that a mechanical massage of  the 
abdominal wall does not modify colonic gas evacuation, 
perception and abdominal distension[86].
An interesting hypothesis is the possibility to correct 
the abnormal abdominal-phrenic coordination, which, 
as mentioned above, is one of  the theories involved in 
the abdominal bloating genesis. Preliminary data show 
the effectiveness of  a new treatments based on correc-
tion of  inappropriate diaphragm contraction with bio-
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Abnormal viscerosomatic reflexes - 
abdomino-phrenic discoordination 








Figure 4  Altered intra-abdominal volume displacement as possible ex-
planation of bloating. Bloating patients show an impaired abdomino-phrenic 
coordination with a paradoxical contraction of the diaphragm coupled with a 
relaxation of the abdominal wall leading to a modification in abdominal girth. 
Adapted from[129].
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Table 1  Summary of randomised clinical trials specifically as-
sessing bloating reliefs
feedback techniques to prevent anterior protrusion of  
the abdominal wall and so manage bloating[109].
A second widely used approach to treat bloating is 
the use of  antibiotics and/or probiotics. The rationale 
underling this drug is that an intestinal dysbiosis could 
increase gas production. In 2006, Sharara et al[110] dem-
onstrated that a 10 d course of  rifaximin is effective in 
reducing bloating symptoms without significant adverse 
events. Also, another interesting double blind, random-
ized, placebo-controlled trial, showed that patients with 
IBS (based on Rome Ⅰ criteria) treated with rifaximin 
reported a significant improvement in bloating and IBS 
symptoms compared to patients who received placebo (p 
= 0.010)[111].
The same group in 2011 analyzing data from 2 large, 
double-blind, placebo-controlled studies for a total of  
1260 non-constipated IBS patients (TARGET 1 and 2) 
found that, compared to placebo, patients in the rifaxi-
min group were more likely to have adequate relief  of  
bloating (p < 0.001)[112].
Regarding the use of  probiotics, conflicting results 
were published in the last years. Most of  the studies were 
limited for relevant methodological limitations, such as 
the use of  different probiotic bacteria in each study and, 
the use of  heterogeneous and not clearly defined study 
population. An interesting study in 2003 showed that in 
Rome Ⅱ IBS-D patients, VSL#3 reduced post-treatment 
abdominal bloating (p = 0.046) and the same Authors in 
the subsequent trial in patients with IBS and significant 
abdominal bloating demonstrated that VSL#3 reduces 
specifically flatulence[113]. A recent trial of  Lactobacillus 
acidophilus and Bifidobacterium lactis in patients with IBS 
found an improvement in bloating severity during an 
8-wk trial period[114].
Conversely, our group found that a in IBS patients 
(Rome Ⅲ criteria) a symbiotic mixture (Probinul, 5 g bid) 
for 4 wk was effective in decreasing the severity of  flatu-
lence in IBS patients, but failed to achieve an improve-
ment in global satisfactory relief  of  flatulence and bloat-
ing[115] although maintenance for further 6 mo still showed 
a benefits on flatulence[116]. 
A recent metanalysis, among different items, specifi-
cally addressed the use of  probiotics in bloating patients 
(Table 1). After including all published trials in which 
probiotics were tested to asses bloating or distension re-
lief  as primary or secondary endpoints in IBS or non IBS 
patients, conclusion was that specific probiotics can lead 
to bloating relief  in some patients with IBS[117].
Experimental data in healthy controls showed that 
glucagon, a potent muscle relaxant, reduced abdominal 
symptoms but gas retention and objective abdominal 
distension were unaffected[77]. Domperidone has been 
shown to be ineffective in IBS symptoms[118] whereas 
the administration of  neostigmine, a prokinetic drug, 
produced gas clearance and improvement of  both ab-
dominal symptoms and objective distension[119]. Likewise 
the 5-HT4 receptor agonist tegaserod has demonstrated 
potent prokinetic effects on small intestinal and colonic 
transit in IBS patients with constipation, also reducing 
the symptoms of  bloating[120]. Ischemic cardiac effects 
have been reported with tegaserod used in a patient 
population at potentially high risk of  cardiovascular 
complications[121-123]. For these reasons, its use in clinical 
practice is very limited. Prucalopride is a highly selective 
5-HT4 receptor agonist with strong enterokinetic activ-
ity[124,125] and requires lower dose for this therapeutic ef-
fect[119] making this drug potentially suitable for bloating 
patients[126]. Itopride, a dopamine receptors antagonist 
and acetylcholinesterase inhibitor, has shown conflicting 
results in patients with functional dyspepsia[127,128].
Other commonly used drugs to relieve bloating and 
more general IBS symptoms are antispasmodics (includ-
ing peppermint oil), gas reducing agents such as simethi-
cone and tricyclic antidepressants (TCAs).
Antispasmodics, such as mebeverine, otilonium, and 
trimebutine, act decreasing the tone and contractility of  
intestinal smooth muscle by an antimuscarinic effect. 
Those drugs are widely prescribed and whereas scientific 
evidence on relieving IBS symptom exists[129], efficacy 
on bloating is under discussion[130]. In a meta-analysis of  
therapeutic options in IBS, Ford et al[131] reviewed clinical 
trials on peppermint oil in IBS patients. Authors’ con-
clusions were that it was superior to placebo, although 
with a statistically significant heterogeneity among those 
studies (4 in total). In 2013, Khanna et al[132], reviewing 
published data on this drug, concluded that peppermint 
oil is significantly superior to placebo in controlling both 
IBS symptoms and abdominal pain with some minor 
and brief  adverse events (manly heartburn).
As regard to gas adsorbing agents, the first licensed 
for bloating symptoms was metylpolysiloxane or sylox-
one then substituted by simethicone[133]. A combination 
of  simethicone plus activated charcoal and magnesium 
oxide was tested against placebo in a double blind, ran-
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Agent Main outcome on bloating symptom Rome 
criteria
Probiotics Bifidobacterium bifidum MIMBb75: Improving 
bloating/distension[136]
Ⅱ
Lactobacillus plantarum 299v: improvement[137] Ⅲ
Multispecies: improvement[138] Ⅲ
Symbiotics Symbiotic mixture: no benefits[115,116] Ⅲ
Antibiotics Rifaximin: reduction in bloating-specific 
scores[110]
Ⅱ
Rifaximin: improvement (39.5% vs 28.7%)[112] Ⅱ
Prokinetics Tegaserod: improvement[120] Ⅰ
Tegaserod: improvement[139-141] Ⅱ
Tegaserod: no differences vs placebo[142] Ⅱ
Prucalopride: improvement[126] Ⅱ
Antispasmodic Otilonium bromide improvement[143] Ⅱ
Mebeverine vs Otilonium bromide: improve-
ment significantly achieved by both treat-
ments[144]
Ⅱ
Antidepressant Paroxetine: no difference vs placebo[145] Ⅰ
Citalopram: improvement[146] Ⅱ
Fluoxetine: improvement[147] Ⅱ
Iovino P et al . Bloating and functional gastro-intestinal disorders
domized, multicenter trial in patients with FD meeting 
the Rome Ⅲ criteria[134]. This study showed a reductions 
in the intensity of  post-prandial fullness, epigastric pain, 
epigastric burning and bloating in the active treatment 
arm compared to placebo[134].
Low dose of  antidepressants are effective treatment 
for IBS. The rationale behind the use of  these drugs is 
that at low dosage they act, through an anticholinergic ef-
fect, similarly to spasmolytics agents. A recent systematic 
review and meta-analysis of  12 randomized controlled 
trials showed that TCAs are effective in the treatment of  
IBS while there is less high-quality evidence for psycho-
logical therapies in IBS[135].
In conclusion, advances in the understanding of  func-
tional bloating have accelerated in the past decade owing 
to increased attention placed on the definition and diag-
nostic criteria, and inroads into the understanding of  the 
underlying pathophysiology. Other studies that may also 
add significant breakthroughs in therapy are welcomed.
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